These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24857631)

  • 1. Dual histamine H3R/serotonin 5-HT4R ligands with antiamnesic properties: pharmacophore-based virtual screening and polypharmacology.
    Lepailleur A; Freret T; Lemaître S; Boulouard M; Dauphin F; Hinschberger A; Dulin F; Lesnard A; Bureau R; Rault S
    J Chem Inf Model; 2014 Jun; 54(6):1773-84. PubMed ID: 24857631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.
    Sadek B; Schwed JS; Subramanian D; Weizel L; Walter M; Adem A; Stark H
    Eur J Med Chem; 2014 Apr; 77():269-79. PubMed ID: 24650714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.
    Yahiaoui S; Hamidouche K; Ballandonne C; Davis A; de Oliveira Santos JS; Freret T; Boulouard M; Rochais C; Dallemagne P
    Eur J Med Chem; 2016 Oct; 121():283-293. PubMed ID: 27266998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.
    Rochais C; Lecoutey C; Gaven F; Giannoni P; Hamidouche K; Hedou D; Dubost E; Genest D; Yahiaoui S; Freret T; Bouet V; Dauphin F; Sopkova de Oliveira Santos J; Ballandonne C; Corvaisier S; Malzert-Fréon A; Legay R; Boulouard M; Claeysen S; Dallemagne P
    J Med Chem; 2015 Apr; 58(7):3172-87. PubMed ID: 25793650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present).
    Łażewska D; Kieć-Kononowicz K
    Expert Opin Ther Pat; 2014 Jan; 24(1):89-111. PubMed ID: 24131059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
    Gao Z; Hurst WJ; Czechtizky W; Francon D; Griebel G; Nagorny R; Pichat P; Schwink L; Stengelin S; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6141-5. PubMed ID: 24076172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on molecular properties prediction and histamine H3 receptor affinities of novel ligands with uracil-based motifs.
    Lipani L; Odadzic D; Weizel L; Schwed JS; Sadek B; Stark H
    Eur J Med Chem; 2014 Oct; 86():578-88. PubMed ID: 25218907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationship studies in serotonin 5-HT4 receptor ligands based on a benzo[de][2,6]naphthridine scaffold.
    Castriconi F; Paolino M; Giuliani G; Anzini M; Campiani G; Mennuni L; Sabatini C; Lanza M; Caselli G; De Rienzo F; Menziani MC; Sbraccia M; Molinari P; Costa T; Cappelli A
    Eur J Med Chem; 2014 Jul; 82():36-46. PubMed ID: 24871995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H
    Szczepańska K; Karcz T; Mogilski S; Siwek A; Kuder KJ; Latacz G; Kubacka M; Hagenow S; Lubelska A; Olejarz A; Kotańska M; Sadek B; Stark H; Kieć-Kononowicz K
    Eur J Med Chem; 2018 May; 152():223-234. PubMed ID: 29723785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New lead elements for histamine H
    Espinosa-Bustos C; Frank A; Arancibia-Opazo S; Salas CO; Fierro A; Stark H
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2890-2893. PubMed ID: 30025902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the development of histamine H
    Łażewska D; Kieć-Kononowicz K
    Expert Opin Ther Pat; 2018 Mar; 28(3):175-196. PubMed ID: 29334795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists.
    Wijtmans M; Celanire S; Snip E; Gillard MR; Gelens E; Collart PP; Venhuis BJ; Christophe B; Hulscher S; van der Goot H; Lebon F; Timmerman H; Bakker RA; Lallemand BI; Leurs R; Talaga PE; de Esch IJ
    J Med Chem; 2008 May; 51(10):2944-53. PubMed ID: 18433114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of histamine H3 receptor ligands on the rewarding, stimulant and motor-impairing effects of ethanol in DBA/2J mice.
    Nuutinen S; Vanhanen J; Pigni MC; Panula P
    Neuropharmacology; 2011 Jun; 60(7-8):1193-9. PubMed ID: 21044640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticonvulsant properties of histamine H3 receptor ligands belonging to N-substituted carbamates of imidazopropanol.
    Sadek B; Shehab S; Więcek M; Subramanian D; Shafiullah M; Kieć-Kononowicz K; Adem A
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4886-91. PubMed ID: 23891186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel lead in the group of N-substituted piperazine ether derivatives with potential histamine H3 receptor activity.
    Kuder KJ; Stachnik M; Schunack W; Szymańska E; Kieć-Kononowicz K
    Med Chem; 2014; 10(6):588-99. PubMed ID: 24047214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural modifications in the distal, regulatory region of histamine H
    Szczepańska K; Pockes S; Podlewska S; Höring C; Mika K; Latacz G; Bednarski M; Siwek A; Karcz T; Nagl M; Bresinsky M; Mönnich D; Seibel U; Kuder KJ; Kotańska M; Stark H; Elz S; Kieć-Kononowicz K
    Eur J Med Chem; 2021 Mar; 213():113041. PubMed ID: 33261900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using electrophysiology and in silico three-dimensional modeling to reduce human Ether-à-go-go related gene K(+) channel inhibition in a histamine H3 receptor antagonist program.
    Davenport AJ; Möller C; Heifetz A; Mazanetz MP; Law RJ; Ebneth A; Gemkow MJ
    Assay Drug Dev Technol; 2010 Dec; 8(6):781-9. PubMed ID: 21133680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Identification of a HEK-293 cell line containing stably-transfected H3R gene and screening for novel non-imidazole histamine H3 receptor antagonists].
    He P; Tan L; Hu W; Dai H; Hu Y; Chen Z
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 May; 42(3):276-82. PubMed ID: 23801615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
    Gbahou F; Vincent L; Humbert-Claude M; Tardivel-Lacombe J; Chabret C; Arrang JM
    Br J Pharmacol; 2006 Apr; 147(7):744-54. PubMed ID: 16432504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel and highly potent histamine H3 receptor ligands. Part 3: an alcohol function to improve the pharmacokinetic profile.
    Labeeuw O; Levoin N; Poupardin-Olivier O; Calmels T; Ligneau X; Berrebi-Bertrand I; Robert P; Lecomte JM; Schwartz JC; Capet M
    Bioorg Med Chem Lett; 2013 May; 23(9):2548-54. PubMed ID: 23535326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.